MAPT and Alzheimer disease: Over the last two decades, the increasing adoption of Alzheimer's disease (AD) biomarkers, such as cerebrospinal fluid (CSF) β-amyloid and tau, as well as nuclear medicine biomarkers indicating amyloid and tau deposition, has improved clinicians’ diagnostic accuracy in regular practice [[1], [2], [3], [4]].